Form Approved
OMB No.: 0920-xxxx
Expiration Date: XX/XX/XXXX
Public Reporting burden of this collection of information is estimated at 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NW, MS D-74, Atlanta, GA 30333; Attn: PRA (0920-XXXX).
Master Interview Guide PDO/naloxone grantees
Hello, this is _______________ with Battelle. Thank you for agreeing to participate in today’s interview. Battelle is a research organization and we are working with CDC and SAMHSA to conduct an evaluation of the SAMHSA-funded grants to Prevent Prescription Drug/Opioid Overdose-Related Deaths, or the PDO/Naloxone grant. The evaluation is intended to help understand the scope and impact of the program on overdose fatalities, increase our understanding of program effectiveness, and increase understanding of barriers and facilitators to program implementation. You have been asked to participate in an interview because you are involved in this work and we are interested in learning about your perspective and experiences with the PDO/naloxone grant.
If you agree to participate in the interview, we will ask you a series of questions related to the PDO/naloxone activities that are occurring in your jurisdiction. This interview will take about 60 minutes or less of your time. Your participation is completely voluntary. You can decide whether or not to participate. If you do agree to participate, you may stop at any time. You may also choose to not answer any questions. Should you choose to participate, your answers will be maintained in a secure manner and you will not be identified by name or description in any reports.
Do you have any questions for me?
Are you willing to participate in the interview?
We would also like to audio tape the interview for transcribing purposes only. You will not be identified by name or description in any of the audio recordings. Once the interviews have been transcribed, the tapes will be erased.
Are you willing to have the interview audio taped?
[Begin recording]
First, please tell us about your role with the PDO/naloxone grant?
[The following questions will be asked during the first round of data collection and as needed during subsequent years]
Planning and Building Infrastructure
Can you describe the process of forming the PDO advisory committee?
Probe: Why were specific members selected?
Probe: Had you worked with these partners before?
Did you encounter any difficulties in forming the PDO advisory committee? If so, how were these difficulties addressed?
Probe: What if anything could have been done differently or more effectively?
When thinking about any systems you developed or use for tracking and monitoring data related to the PDO/naloxone grant, what works well? What aspects do not work as well or could be improved?
When thinking about the start of the PDO/naloxone grant and your initial planning to begin this work, can you tell me about what worked well and what aspects were more challenging?
Probe: How did you address any challenges during the planning stage?
How has the PDO/naloxone funding helped develop or increase infrastructure to reduce the number of prescription drug/opioid overdose-related deaths and adverse events?
Probe: What infrastructure was lacking prior to receiving the grant?
[The following questions are asked during all rounds of data collection]
Partnerships and Collaboration
How do you collaborate and work with partners to implement the PDO/naloxone grant?
Probe: To provide education/training? To distribute/increase access to naloxone?
Probe: Why were specific partners selected?
Probe: Had you worked with these partners before?
What have you seen as the benefits of these collaborations and partnerships?
What challenges were encountered when working in these partnerships and how were they addressed?
Education and Training
Please briefly describe how naloxone education and training is being provided? [In subsequent years can ask about whether there have been any changes]
Probe: Who provides this? Partners, the grantee’s organization?
Probe: How does education and training vary by audience?
What approaches do you think work best when providing naloxone education and training? Which approaches are least effective?
What factors facilitate the process of providing education and training to various audiences?
What factors were barriers or challenges to providing training and education?
Distribution
Please briefly describe how naloxone is being distributed? (If distributed directly to communities, ask about that. If distributed to partner organizations, ask about that.)
What factors facilitate distribution of naloxone? What factors impede distribution or presented challenges?
Probe: How were those challenges addressed?
Disparities
What approaches do you use to address disparities in your PDO/naloxone work?
Probe: What approaches are most successful and why?
Probe: What approaches don’t seem to work as well or are challenging?
Probe: Which populations were reached by your efforts?
Policies
What impact did state or local support for naloxone have on your work?
Probe: What impact did state/local policies/laws have?
Probe: Which particular state/local policies or laws impacted the work?
Year 3 and 4 Questions [Questions to be asked during later rounds of data collection]
What would you consider key accomplishments of your program or partners' work on the PDO naloxone grant?
When thinking about your work on the PDO/naloxone grant, what factors facilitated program implementation? What factors impeded program implementation?
What program elements are most successful? Why?
What program elements are least successful? Why?
Do you think the changes that have been created in your community, or the infrastructure that was developed as a result of this grant can be sustained after the funding? How will changes be sustained?
How could future versions of PDO/naloxone funding be improved?
In what ways do you think stakeholder support for naloxone has changed during the funding period?
Is there anything else you think is important to our evaluation that you’d like to share?
Conclusion
Thank you so much for your time today. Your input will help us better understand how the PDO/naloxone grant funding is being used in your community. What we learn from this will help other communities in the future as well. So, again, thank you.
| File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| Author | Chovnick, Gary |
| File Modified | 0000-00-00 |
| File Created | 2021-01-21 |